Jaume Pons

Jaume Pons

Founder at
Alx Oncology Ltd.

Net worth: 939 966 $ as of 30/05/2026

60 year
Health Technology
Consumer Services
Finance

Profile

Dr. Jaume Pons is a President, Chief Executive Officer & Director at ALX Oncology Ltd. and a Scientific Advisor at LSV Capital Management LLC.
He is on the Board of Directors at ALX Oncology Ltd., Alexo Therapeutics International, Sirpant Therapeutics and Tallac Therapeutics, Inc. Dr. Pons was previously employed as a President & Chief Scientific Officer by ALX Oncology Holdings, Inc., a Venture Partner by venBio Partners LLC, a Chief Scientific Officer by Rinat Neuroscience Corp., a President & Chief Executive Officer by ALX Oncology, Inc., and a Chief Technology Officer by Pfizer Inc. He received his undergraduate degree from Autonomous University of Barcelona, a graduate degree from the University of California, Berkeley, a graduate degree from Autonomous University of Barcelona and a doctorate degree from Autonomous University of Barcelona.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
30/03/2026 494,719 ( 0.37% ) 939 966 $ 30/05/2026

Jaume Pons active positions

CompaniesPositionStart
Founder 31/03/2015
Director/Board Member -
Founder -
Sirpant Therapeutics
Director/Board Member -
Consultant / Advisor -

Former positions of Jaume Pons

CompaniesPositionEnd
ALX ONCOLOGY HOLDINGS INC. Chief Executive Officer 05/09/2023
Chief Tech/Sci/R&D Officer 31/01/2015
PFIZER INC. Chief Tech/Sci/R&D Officer -
Chief Executive Officer -
░░░░░░ ░░░░░░░░ ░░░ ░░░░░░░ ░░░░░░ ░░░░░░░░ -
See the detail of Jaume Pons's experience

Training of Jaume Pons

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

94

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Technology

Consumer Services

Health Technology

Finance

Consumer Services

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Sirpant Therapeutics